To better support the application of PDX models in preclinical oncology, especially to guide tumor model selection for better prediction on clinical response in patients, Creative Animodel provides customers well-characterized tumor model database (including cancer type and subtype, stage, grade, histology and harvest site) as well as genotyping analysis in virtue of bioinformatics under given experiment, which is essential for goal-oriented in vivo studies and targeted therapy investigation. Thus, the expertise in Creative Animodel ranges from gene expression via complex genome reconstruction analyses to novel algorithm and application development to solve the complex biological questions which cannot be addressed by generalized “one-fits-all” approaches.
Our service portfolio includes the following categories, but is not limited to:
• Gene Expression Profiles
♦ Targeted Exome Sequencing
This procedure is based on the next generation sequencing (NGS), which can be adopted for mentoring unique biological events like comparing targeted gene alteration from vehicle to experimental treatment arms, or making an evaluation of the differences between non-responsive and responsive tumors in a single study arm.
♦ Whole Exome Sequencing (WES or WXS)
The goal of this approach is to identify genetic variation that is responsible for tumor generation or progression without the high costs associated with whole-genome sequencing. Besides we also provide large structural rearrangement analysis and de novo genome assembly
♦ Whole Transcriptome Sequencing
RNA-seq based transcriptome analysis of the PDX models in Creative Animodel supports the investigation of alternative splicing, differential expression (gene and/or isoform), gene fusion and mutation in cancer progression and pharmaceutical responses, allowing the investigation of gene and pathway deregulation as well as the identification of new therapeutic targets. The final readouts can be presented as follows: transcript quantification, heat map indicating differential expression of control/treatment or pre/post-intervention.
• Mutational Analyses
For the reasons that SNPs and CNVs are determinants of cancer outcome and response to targeted therapies, investigations into this area are of great importance for chemotherapeutic exploration. Our related detection services aim at:
The following information will be available to the customers which including:
The highly customizable analysis workflows, a wide range of state-of-the-art bioinformatics methods as well as the novel algorithm development by PDX characterization platform in Creative Animodel will help you achieve a better understanding of the molecular basis of tumor sensitivity/resistance to chemotherapeutics or drug candidates, as well as accelerate your identification process of undetermined biomarkers.